Hospital Pharmacy - December 2017 - 773

Pereira et al.
Based on both physical appearance and chemical composition, extemporaneously prepared dNCS can be stored for
up to 30 days under refrigeration at 4°C in EVA bags for
standard usage.
Our institution currently requires commercially prepared
dNCS to be utilized, as per recent state legislation (ie,
Pharmacy Practice Act, Commonwealth of Massachusetts,
House Bill, No. 3672, amended, accompanying bill (House,
No. 4235), June 29, 2014). Whenever in-house preparation
becomes required again, we will modify our dNCS labels for
a 30-day expiration date when kept refrigerated at 4°C.

Conclusions
The dNCS is stable for at least 30 days under 4°C refrigeration. No degradation products are generated during this storage time in EVA bags under these conditions for the
components measured.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Hughes CF, Grant AF, Leckie BD, Baird DK. Cardioplegic
solution: a contamination crisis. J Thorac Cardiovasc Surg.
1986;91(2):296-302.
2. Matte GS, del Nido PJ. History and use of del Nido cardioplegia solution at Boston Children's Hospital. J Extra Corpor
Technol. 2012;44:98-103.

773
3. O'Blenes SB, Friesen CH, Ali A, Howlett S. Protecting the
aged heart during cardiac surgery: the potential benefits of del
Nido cardioplegia. J Thorac Cardiovasc Surg. 2011;141:762770.
4. Guyton RA. The myocardium: physiology and protection during cardiac surgery and cardiopulmonary bypass. In: Mora
CT, ed. Cardiopulmonary Bypass. New York, NY: SpringerVerlag; 1995: 21-39.
5. O'Brien JD, Howlett SE, Burton SJ, O'Blenes SB, Litz
DS, Friesen CLH. Pediatric cardioplegia strategy results in
enhanced calcium metabolism and lower serum troponin T.
Ann Thorac Surg. 2009;87:1517-1523.
6. Charette K, Gerrah R, Quaegebeur J, et al. Single dose myocardial protection technique utilizing del Nido cardioplegia
solution during congenital heart surgery procedures. Perfusion.
2012;27:98-103.
7. Kim K, Ball C, Grady P, Mick S. Use of del Nido cardioplegia for adult cardiac surgery at the Cleveland Clinic:
perfusion implications. J Extra Corpor Technol. 2014;46:
317-323.
8. Mick SL, Robich MP, Houghtaling PL, et al. del Nido versus Buckberg cardioplegia in adult isolated valve surgery. J
Thorac Cardiovasc Surg. 2015;149(2):626-634.
9. Pharmaceutical compounding-sterile preparations (general
information chapter 797). In: The United States Pharmacopeia,
and the National Formulary (36th rev., 31st ed.). Rockville,
MD: United States Pharmacopeial Convention; 2013:361-398.
10. Guidance for Industry: Drug Stability Guidelines. US
Department of Health and Human Services, Food and Drug
Administration, Center for Veterinary Medicine (CVM); 2008.
11. Merbel N, Savoie N, Yadav M, et al. Stability: recommendation for best practices and harmonization from the
Global Bioanalysis Consortium Harmonization Team. AAPS J.
2014;16(3):392-399.
12. USP Compounding Expert Committee. Strength and Stability
Testing for Compounded Preparations. Rockville, MD: US
Pharmacopeial Convention; 2014.

Table of Contents for the Digital Edition of Hospital Pharmacy - December 2017